Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 3,100 shares, a decrease of 27.9% from the October 15th total of 4,300 shares. Based on an average trading volume of 14,400 shares, the days-to-cover ratio is presently 0.2 days.
Adlai Nortye Trading Up 3.8 %
Shares of Adlai Nortye stock traded up $0.12 on Thursday, reaching $3.27. The stock had a trading volume of 24,954 shares, compared to its average volume of 11,640. The business's 50 day moving average is $2.16 and its two-hundred day moving average is $4.52. Adlai Nortye has a 1 year low of $1.85 and a 1 year high of $17.48.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a "buy" rating and set a $9.00 price target on shares of Adlai Nortye in a research report on Monday.
View Our Latest Report on ANL
Adlai Nortye Company Profile
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Recommended Stories
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
